Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Ayuda Buscar en la ayuda Buscar en la ayuda Successfully Treating Pulmonary Arteriovenous Malformation and Pulmonary Arterial Hypertension in a Patient with GDF2 Variant Junjing Su [1] ; Michael Rahbek Schmidt [1] ; Laurence Campens [1] ; David Montani [2] ; David G.
The study was supported by Novartis HealthCare A/S. The funder had no role in the preparation of the manuscript or decision to publish. JA has received speaker fees from Novartis HealthCare A/S. AB has received speaker fees, consulting fees and travel support from Novartis HealthCare A/S.
Pulmonary arterial hypertension (PAH) is characterized by distal vasoconstriction, vascular remodeling, microvascular injury, and thrombosis leading to increased pulmonary vascular resistance (PVR) and elevated mean pulmonary arterial pressure (PAPm).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
